1. Introduction {#s0005}
===============

Incidence rates of both osteoporosis and breast cancer increase with age. Just like osteoporosis ([@bb0090], [@bb0085]), breast cancer is a major public health problem, with incidence rates expected to rise over the next years ([@bb0010]). Several risk factors for breast cancer have been identified many of which (e.g. early menarche, late menopause, breast feeding and hormone replacement therapy) are related to prolonged estrogen exposure ([@bb0100]). The physiological action of estrogen may link breast and bone pathologies ([@bb0100], [@bb0120]). Since estrogen regulates bone turnover, high bone mineral density (BMD) may be regarded as marker for prolonged cumulative estrogen exposure ([@bb0175]).

Measurement of BMD is utilized to assess the osteoporotic status of bone for the prevention of osteoporotic fractures, for which the standard method is dual-energy X-ray absorptiometry (DXA) of the lumbar spine, femoral neck or total hip. BMD could reflect long-term exposure to estrogens and hence serve as intermediate marker of breast cancer risk.

Because estrogen affects both BMD and breast cancer risk, it has been hypothesized that women with high BMD are at increased risk to develop breast cancer. Other potential mechanisms could be related to physical activity and vitamin D intake and activation. There is indeed evidence from a previous meta-analysis that BMD and breast cancer risk are positively correlated ([@bb0165]). However, results therein are based on reports varying in study designs, age groups, as well as measurement methods and sites. Moreover, most of these studies were performed among women over 60 years with DXA measurements of the hip ([@bb0030], [@bb0160], [@bb0070], [@bb0115], [@bb0040]). Considering the long latency time for developing breast cancer, however, measurements at younger age with longer follow-up may be more appropriate.

The aims of our study were to investigate the association between BMD and breast cancer risk among women in a large prospective cohort study with long-term follow-up and to quantify the evidence of a relationship between BMD and breast cancer risk in a meta-analysis including prospective studies.

2. Patients and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

Within the framework of the Vorarlberg Health Monitoring & Prevention Program (VHM&PP), 4550 women were recruited between July 1991 and May 1999 for a prevention activity especially tailored for women with climacteric complaints, i.e. "Women-50plus" that has been described in detail before ([@bb0045]). In brief, data on physical and mental well-being, medication, physical activity and smoking status were collected by questionnaire, and height, weight and blood pressure were measured. Ethical approval for the evaluation of the VHM&PP data was obtained by the ethics committee of Vorarlberg. In order to identify women with osteoporosis, bone mineral density was measured at recruitment. Baseline BMD of 4107 women has been measured by dual energy X-ray absorptiometry (DXA, N = 1418) or quantitative computer tomography (QCT, N = 2689) depending on the place of residence.

2.2. Exposure {#s0020}
-------------

Overall, 1418 women underwent DXA scanning at the lumbar spine at baseline. After exclusion of prevalent breast cancer cases and data due to missing and implausible values, BMD data of 1380 women were available for the analyses.

Quartile cut-points were defined for DXA. In addition, we transformed the original values to standardized variables (z-scores) with zero as mean and one as standard deviation. Hence the z-score was calculated as: z = (x − μ)/σ, where μ is the mean, σ is the standard deviation, and x is the actual level of the exposure.

2.3. Outcome {#s0025}
------------

Incident breast cancer cases were identified in the Vorarlberg cancer registry in accordance with the code C50 of the International Classification of Diseases, 10th revision (ICD-10). Data on vital status were obtained from the mortality registry at Statistics Austria. Person-years under observation for each woman were calculated until the date of cancer diagnosis or the date of death, whichever came first. Participants were censored by December 31, 2011.

2.4. Covariates {#s0030}
---------------

Adjustment has been performed for body mass index (BMI, kg/m^2^), smoking status (smoker, ex-smoker, non-smoker), hormone replacement therapy (HRT) use (yes, no), menstrual cycle duration (menses, \< 30, 30--40, \> 40 years), hysterectomy (yes, no), menopausal status (\< 50, ≥ 50 years), use of thyroid medication (yes, no), and leisure time physical activity (none, 30 min, 30--60 min, 60--120 min, \> 120 min/week).

2.5. Statistical analysis {#s0035}
-------------------------

A cohort study design was used in order to investigate the association between DXA and breast cancer risk. Bivariate comparisons of women who developed breast cancer and those who did not were performed using *t*-test for continuous variables and χ^2^-test for categorical variables. Cox proportional hazards models were fitted to obtain Hazard Ratios (HRs) with 95% confidence intervals (CIs) for breast cancer. The models were adjusted for age at recruitment (years) and smoking status (four categories: never, former, current smokers and unknown). Additional models were calculated adjusting for BMI, menstrual cycle duration, HRT use, leisure time physical activity and thyroid medication.

2.6. Meta-analysis {#s0040}
------------------

A systematic literature research limited to publications in English, has been carried out using Medline PubMed (1980 till December 31, 2014) using abstracts, titles and MeSH headings. For the exposure we searched the terms "bone mineral density", "bone density", "BMD" and for the outcome "breast cancer", "breast tumor" and "Breast Neoplas\*". PubMed search term: bone mineral density\[Title/Abstract\] OR bone density\[Title/Abstract\] OR BMD\[Title/Abstract\] OR Bone Density\[MH\]) AND (breast cancer\[Title/Abstract\] OR breast tumor\[Title/Abstract\] OR Breast Neoplas\* OR Breast Neoplasms\[MH\]) AND English\[Language\] AND ("1980/01/01"\[PDAT\]: "2014/12/31"\[PDAT\]). In addition, the references lists were screened for relevant publications.

Two reviewers evaluated the studies with respect to the inclusion criteria and the predefined quality indicators. Inclusion criteria were: 1) cohort or case-control study, 2) BMD as exposure variable, 3) breast cancer as outcome variable, and 4) the report of a relative risk estimate. In case of discrepancies, a consensus was reached by discussion. Studies in which other methods than DXA were applied were not included in the meta-analysis. Furthermore, a standardized reporting form was used to collect the following relevant data: first author\'s name, publication year, location of the study, study design, menopausal status, BMD assessment, BMD measurement site, sample size, number of breast cancer cases, relative risk estimates and confidence limits, units of measurements and analysis, and comments. Categorical and dose-response meta-analyses were conducted using random-effects models. We did not distinguish between different types of relative risk estimates (risk, rate or odds ratio) based on the assumption that breast cancer is sufficiently rare. Summary relative risks (RRs) were used as common measure of association. The maximally adjusted risk estimates were used for the meta-analysis. For categorical meta-analyses, RRs for the highest versus lowest BMD category were used. For the dose response meta-analyses, estimates for continuous associations were transformed to represent the RR associated with a 0.1 g/m^2^ increase in BMD.

To assess heterogeneity, the Cochran Q-test and I^2^ statistics were applied. The inverse of the variance of estimates was used as weight and the restricted maximum likelihood estimator was used to quantify heterogeneity. The I^2^-values at 25%, 50%, and 75% served as cut-points to define low, moderate and substantial heterogeneity, respectively ([@bb0095]). Funnel plots were displayed to explore publication bias (see [Supplemental Figure](#ec0005){ref-type="supplementary-material"}).

P-values \< 0.05 were considered statistically significant. Calculations were carried out with SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). All meta-analyses were conducted using R (R Foundation for Statistical Computing, Vienna, Austria), version 3.0.1.

3. Results {#s0045}
==========

During mean follow-up of 16.3 (SD 3.3) years, 52 cases of invasive breast cancer were identified in 1380 women ([Table 1](#t0005){ref-type="table"}). At baseline, mean age was 55 (SD 6.3) years and mean BMI was 25.2 (SD 3.9) kg/m^2^. Of the participants, 27.5% were ever smokers, 21.4% reported HRT use, and 16.8% reported to perform more than two hours of sports per week. The overall mean of DXA results was 0.94 (SD 0.16) g/cm^2^, with no statistically significant difference for women who developed breast cancer (0.92 g/cm^2^). Concerning the covariates, no statistically significant differences were observed.Table 1Baseline characteristics of the study population.Table 1All subjectsNo breast cancerBreast cancerP-valuen = 1380n = 1328n = 52Age (years), mean (SD)55.45 (6.3)55.5 (6.3)55.1 (5.3)0.677BMI (kg/m^2^),mean (SD)25.2 (3.9)25.2 (4.0)24.9 (3.7)0.547DXA, lumbar spine (g/cm^2^), mean (SD)0.94 (0.16)0.94 (0.16)0.92 (0.19)0.559Leisure time physical activity (sports), N (%)0.399 Max. 30 min731 (53.0)699 (52.6)32 (61.5) ½ h--2 h417 (30.2)403 (30.4)14 (26.9) \> 2 h232 (16.8)226 (17.0)6 (11.5)Smoking status, N (%)0.927 Never1000 (72.5)962 (72.5)38(73.1) Ever379 (27.5)365 (27.5)14 (26.9)Menstrual cycles duration, N (%)0.544 \< 30 years310 (27.0)295 (26.3)15 (33.3) 30--40 years783 (67.2)755 (67.4)28 (62.2) \> 40 years73 (6.3)71 (6.3)2 (4.4)HRT use, N (%)0.995 No1062 (77.0)1022 (77.0)40 (76.9) Yes318 (23.0)306 (23.0)12 (23.1)Hysterectomy, N (%)0.748 No954 (69.1)917 (69.1)37 (71.2) Yes426 (30.9)411 (31.0)15 (28.9)Thyroid medication, N (%)0.428 No1271 (92.1)1221 (91.9)50 (96.2) Yes109 (7.9)107 (8.1)2 (3.9)[^2]

[Table 2](#t0010){ref-type="table"} shows the associations between quartiles of bone mineral density and breast cancer risk. Compared with the lowest quartile of DXA results, HRs for breast cancer risk were statistically non-significantly reduced at higher quartiles of BMD (for example, HR 0.79, 95% CI: 0.36--1.70 for the 4th quartile in the fully adjusted model). The results for DXA z-scores adjusted for different variables are shown in [Table 3](#t0015){ref-type="table"}. In the fully adjusted model, DXA z-scores were non-significantly associated with reduced breast cancer risk (HR 0.91, 95% CI 0.67--1.23). Adjustment for different potential confounders did not substantially influence the estimates.Table 2Hazard Ratios (HRs) of breast cancer risk according to quartiles of bone mineral density by DXA at the lumbar spine.Table 2DXACasesBasic model[a](#tf0005){ref-type="table-fn"}Fully adjusted model[b](#tf0010){ref-type="table-fn"}Measurement for BMD(g/cm^2^)NHR (95% CI)HR (95% CI)1st quartile\< 0.83171 (ref.)1 (ref.)2nd quartile0.83--0.925100.548 (0.249--1.207)0.555 (0.251--1.228)3rd quartile0.926--1.033110.606 (0.279--1.316)0.623 (0.284--1.367)4th quartile\> 1.033140.754 (0.358--1.587)0.787 (0.364--1.701)[^3][^4][^5]Table 3Hazard Ratios (HRs) of breast cancer risk for z-score of DXA at the lumbar spine adjusted for different confounders.Table 3BMD measurementNHR (per 1 z-score increase)95% CIDXAAdjusted for age13800.8920.665--1.196 + BMI13630.9130.913--1.234 + sports13800.8930.667--1.198 + smoking status13790.8920.665--1.196 + menses11660.9020.657--1.239 + HRT use13800.8920.665--1.196 + Thyroid medication13800.8910.665--1.196 + Hysterectomy13800.8940.666--1.199Fully adjusted model[a](#tf0015){ref-type="table-fn"}13620.9080.670--1.230[^6][^7]

3.1. Meta-analysis {#s0050}
------------------

Our database search rendered 987 hits (most related to breast cancer metastasis or treatment) of which 24 were retrieved for eligibility with BMD as potential risk factor ([Fig. 1](#f0005){ref-type="fig"}). In addition, the references lists were screened for further relevant publications but did not provide any such.Fig. 1Flow diagram of study selection.Fig. 1

Of those 24 publications, we excluded six due to a method other than DXA: the MABOT study due to quantitative ultrasonometry ([@bb0080]), the NHANHES I and the Framingham study due to Osteo Gram Radiographic Absorptiometry ([@bb0155], [@bb0190]), and the Study of Osteoporotic Fractures (SOF) using single-photon absorptiometry ([@bb0145], [@bb0150], [@bb0195]).

Among the remaining 18 publications, we identified two with data of the Fracture Intervention Trial (FIT) ([@bb0020], [@bb0015]), one using the full cohort ([@bb0020]) and one using a nested case control design ([@bb0015]), results of only the former of which were included in the meta-analysis. Likewise, we found two publications of the MORE and CORE trials ([@bb0035], [@bb0025]), of the more recent of which we used the results of the placebo arm ([@bb0025]). Further studies were excluded that reported only combined results for pre- and post-menopausal women ([@bb0060], [@bb0115], [@bb0180], [@bb0185]), or did not report multivariate results comparing cases and controls ([@bb0110]). The characteristics of all 11 publications included in the meta-analysis are listed in [Table 4](#t0020){ref-type="table"}. Results of these studies were combined with the results of our study.Table 4Characteristics of the studies included in the meta-analysis.Table 4StudyCohortDesignFollow-up (years)PositionMean age (years)Total nCases nAdjusted forPresent studyWomen 50 +PC16.3LS55.5138052Age, BMI, physical activity, smoking, HRT[@bb0130]Samsung Medical Center, South KoreaCCnaFN, LS59.2306102Age, BMI, height, smoking, alcohol, family history, HRT, parity[@bb0075]Manitoba BMD register, CanadaPC5.4FN, LS64.737,860794Age, BMI, HRT, corticosteroid use[@bb0025]MORE and CORE trialsPC6.0FN, LS66.5257658Age[@bb0040]Women\'s Health Initiative (WHI), USPC8.4TH63.09941327Age, education, BMI, smoking, alcohol, HRT, ethnicity, GAIL-Score[@bb0140]San Diego community, USCCFN, LS71.823779Age, physical activity, waist circumference, vitamin D intake[@bb0070]Epidémiologie de l\'ostéoporose (EPIDOS), FrancePC7.0FN79.4150445Age, education, BMI, smoking, alcohol, physical activity, HRT, age at menopause, parity, surgical menopause, calcium intake, breast feeding, family income[@bb0135]Rotterdam Study, NetherlandsPC6.5FN, LS68.0310774Age[@bb0065]Study of osteoporotic fractures of Picardie area, FranceCCnaFN, LS58.4252126Age, BMI, smoking, alcohol, family history, parity, age at menarche, age at menopause, calcium intake, breast feeding, diabetes, osteoporosis[@bb0015], [@bb0020]Women screened for inclusion in the Fracture Intervention Trial (FIT), USPC3.7TH68.28203131Age, BMI, geographic area[@bb0160]Dubbo Osteoporosis Epidemiology Study (DOES), AustraliaCCnaFN, LS67.615030Age, BMI, HRT, age at menarche, age at menopause[@bb0030]Study of Osteoporotic Fractures (SOF), USPC3.2LS, TH71.5685497History of benign breast disease[^8]

The results of the meta-analysis for continuous and categorical BMD at different measurement sites are shown in [Fig. 2](#f0010){ref-type="fig"}a--d. The combined risk ratio (RR) for BMD measurements of the lumbar spine revealed a 15% (95% CI 0.99--1.33) increase in breast cancer risk per 0.1 g/m^2^ increase in BMD that just barely failed to reach statistical significance. For BMD at the femoral neck or total hip, however, a statistically significant 16% (95% CI 1.02--1.32) increase in breast cancer risk was found. When the highest BMD category was compared versus the lowest, BMD was associated with increased breast cancer risk independent of the measurement site. The combined RRs for comparison of the extreme BMD categories (highest vs. lowest) were 1.49 (95% CI 1.04--2.13) for the lumbar spine and 1.66 (95% CI 1.26--2.18) for the femoral neck or total hip. The I^2^ values were in the range of 43.8% and 69.3% indicating moderate heterogeneity between the studies.Fig. 2a--d: Meta-analysis of BMD by DXA continuous (a, b) and categorical (c, d) by measurement site (lumbar spine a, c and femoral neck b, d) with breast cancer risk using the random-effects (RE) model.Fig. 2

4. Discussion {#s0055}
=============

In this prospective cohort study, we found no indication for an association between BMD and breast cancer risk during 16.3 years of mean follow-up. While this finding is borne out by a number of previous studies ([@bb0115], [@bb0035], [@bb0180], [@bb0185]), other studies did find an association between BMD measured by DXA at the lumbar spine and breast cancer risk ([@bb0030], [@bb0040], [@bb0065], [@bb0075]). Moreover, the results of our meta-analysis including our data support the hypothesis that BMD is positively associated with breast cancer risk.

Different inclusion criteria, age patterns and follow-up intervals as well as differences in the adjustment for confounding variables may have contributed to divergent findings. For example, [@bb0075] used data of women aged ≥ 50 years from the Manitoba BMD database, and data from clinical trials including women with low BMD were used in other studies ([@bb0035], [@bb0025]). Referrals to BMD measurement may be confounded by unmeasured factors such as medication or vitamin D levels affecting breast cancer risk that were not controlled for in the analyses. In contrast, in our population-based study, women participated in an additive health prevention program ([@bb0045]) where many younger patients not suspected at high risk for fracture were referred to DXA. Therefore, women in our study are likely to be at lower risk for breast cancer than in most previous investigations that included older women on average with an indication for low bone mass. In this regard, risk estimates shown for the BMD at the femoral neck in the population-based Rotterdam Study ([@bb0135]) are quite similar to our results.

Since estrogen is a major regulator of bone metabolism ([@bb0125]) with an influence on breast cancer risk ([@bb0105]), and associations of insulin like growth factors (IGF) and vitamin D with both BMD and breast cancer have been reported ([@bb0005], [@bb0170], [@bb0055]), a biological link between BMD and breast cancer risk is plausible. In fact, [@bb0075] found that among women ≥ 50 years BMD of the lumbar spine was an independent risk factor for breast cancer, in particular if tumors were estrogen-receptor (ER) positive ([@bb0075]), and postmenopausal non-osteoporotic women with low bone mass were reported to be at higher breast cancer risk than postmenopausal osteoporotic patients ([@bb0025]).

A strength of our study is the inclusion of a relatively homogenous age group at the baseline assessment and virtually complete long-term follow-up of \> 16 years. By contrast, one limitation is the possible measurement error of BMD by DXA. However, the measurements were performed at one clinic and potential confounders were considered in the analyses. Another limitation is that our study is arguably not representative of the general Austrian population, because participation in the health check-ups was voluntary, which could have led to the healthy volunteer bias. Even though we had no information on vitamin D and hormone-receptor status, information on drugs was available and so we could consider thyroid medication as co-factor in the models, whereas use of corticoids was reported by too few women (N = 2) to be included in our analyses. A previous investigation reported that about 76% of breast cancers had a positive hormone estrogen receptor (ER) status ([@bb0050]). Unfortunately, we had no information on hormone receptor status, but the prevalence of ER positive breast cancer cases is likely to be similar. However, residual confounding could have affected our results.

The results of the meta-analysis are in line with a previous report on the results of 10 prospective studies ([@bb0165]) showing that women per 1 SD increase in BMD of the hip or spine have a 20% or 26% increased breast cancer risk. In our up-dated meta-analysis including more studies, we found a borderline statistically significant 16% increase in breast cancer risk for the BMD at the femoral neck and 15% for BMD at the lumbar spine.

Most of the included studies reported on BMD measurement by DXA of both measurement sites, i.e. the lumbar spine and femoral neck ([@bb0030], [@bb0025], [@bb0065], 29; [@bb0075], [@bb0135], [@bb0140], [@bb0130]). Our finding of a stronger association for the comparison the extreme categories of BMD measured at the femoral neck/total hip than the lumbar spine is somehow in contrast with previous results ([@bb0165]). However, for the continuous values we found no differences between the site of measurement.

Interpretation of the results of our meta-analysis needs to consider several limitations. Based on the funnel plots, we found little indication for publication bias, but the quality of the included studies varies. Some investigations were based on secondary data analysis ([@bb0075]), clinical trials ([@bb0035], [@bb0025]), and cohort studies ([@bb0040], [@bb0190], [@bb0135]), and adjustment for potential confounding variables differed between publications. Only few studies considered history of benign breast disease ([@bb0030]), history of osteoporosis ([@bb0065]), calcium ([@bb0065]) or vitamin D intake ([@bb0140]) as covariates. Cancer detection methods may have changed over time and may differ between investigations. Moreover, methodological differences could have introduced heterogeneity. However, the calculation of I^2^ indicated moderate heterogeneity for continuous BMD values measured at the femoral neck and the lumbar spine. In addition, the calculation of subgroups of measurement site revealed similar results.

In conclusion, we found no significant association between BMD measured by DXA and breast cancer risk in a population-based cohort of women at mean age of 55 years and long-term follow-up. However, overall the present meta-analysis extends and confirms the association between increasing BMD and increased breast cancer risk in postmenopausal women. The strength of association depended on the measurement site and was slightly stronger when measured at the total hip.

The following is the supplementary data related to this article.Supplemental FigureFunnel plots.Supplemental Figure
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[^1]: Equally contributed.

[^2]: BMI Body mass index, HRT hormone replacement therapy, DXA dual-energy X-ray absorptiometry.

[^3]: BMD bone mineral density, DXA dual-energy X-ray absorptiometry.

[^4]: Adjusted for age at recruitment.

[^5]: Stratified for smoking status and menopausal status and adjusted for age at recruitment, sport, BMI and HRT use.

[^6]: BMD bone mineral density, DXA dual-energy X-ray absorptiometry.

[^7]: Stratified for smoking status and menopausal status and adjusted for age at recruitment, sport, BMI and HRT use.

[^8]: PC: prospective cohort study; CC: case control study. FN: femoral neck; TH: total hip; LS: lumbar spine. BMI: body mass index; HRT: hormone replacement therapy.
